Following Companies

 
Stock Quotes for Following Companies top ^
  • Industry: Banks - Regional - Europe
  • Sector: Financial Services
  • Stock Style: Large Core
  • Morningstar Rating: 3 Stars
Sign-up for xetr%3acbk investment picks
  • Industry: Banks - Regional - Europe
  • Sector: Financial Services
  • Stock Style: Large Core
  • Stock Type: Cyclical
  • Morningstar Rating: 3 Stars
Sign-up for cbk investment picks
  • Industry: Banks - Regional - Europe
  • Sector: Financial Services
  • Stock Style: Large Core
  • Stock Type: Cyclical
Sign-up for cbk investment picks
  • Industry: Banks - Regional - Europe
  • Sector: Financial Services
  • Stock Style: Large Core
Sign-up for czb investment picks
  • Industry: Banks - Regional - Europe
  • Sector: Financial Services
  • Stock Style: Large Core
Sign-up for com investment picks

 
News Articles for Following Companies top ^
Barclays Bank PLC (“Barclays”) and OFI Global Asset Management, which consists of OppenheimerFunds, Inc. and certain of its advisory subsidiaries, announced today that following the close of business on Friday, October 10, 2014, the following Index Constituents will be removed from the Barclays OFI SteelPath Midstream MLP Index (the “Index”): In addition to the above removals and also occurring following the close of business on Friday October 10, 2014, the following five constituents will be added to the Index: MPLX LP (NYSE: MPLX) NuStar GP Holdings LLC (NYSE: NSH) Plains GP Holdings LP (NYSE: PAGP) Tallgrass Energy Partners LP (NYSE: TEP) Valero Energy Partners LP (NYSE: VLP) The Barclays OFI SteelPath MLP ETNs (the
Sign-up for Barclays and OFI Global Asset Management announce the following changes to the Barclays OFI SteelPath Midstream MLP Index investment picks
HOUSTON , Oct.
Sign-up for Main Street Announces Follow-On Investment investment picks
A.M. Best has commented that the financial strength rating (FSR) of A (Excellent) and the issuer credit rating (ICR) of “a” of American Reliable Insurance Company (American Reliable) (Scottsdale, AZ) are unchanged following the announcement that Global Indemnity Group, Inc. (Global Indemnity), a subsidiary of Global Indemnity plc (Ireland) [NASDAQ:GBLI], has agreed to acquire American Reliable, a subsidiary of Assurant, Inc. (Assurant) (headquartered in New York) [NYSE:AIZ]. However, as discussed in detail below, the rating outlook for the ICR, which is currently positive for American Reliable, will likely be revised to stable following the completion of A.M. Best’s evaluation of the transaction after its close.
Sign-up for A.M. Best Comments on the Ratings of American Reliable Insurance Company Following Acquisition Announcement investment picks
http://media.marketwire.com/attachments/201211/54178_rand.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155850&ProfileId=051205&sourceType=1 BUFFALO, NY --
Sign-up for Rand Capital Increases Net Asset Value to $4.47, One New Investment in Crashmob, Inc., Two Follow-On Investments, Sale of QuaDPharma and Continued Stock Repurchase Plan investment picks
The Rubicon Project, Inc. (NYSE: RUBI), a leader in advertising automation and real-time trading platforms for the buying and selling of advertising, will present at the following investor conferences in November 2014: The RBC Capital Markets’ Technology, Internet, Media and Telecommunications Conference, to be held at the Westin Times Square, in New York on Tuesday, November 11 at 3:30PM ET.
Sign-up for Rubicon Project to Present at the Following Upcoming Investor Conferences investment picks
2014/10/30
Combined Entity to be Named Zimmer Biomet WARSAW, Ind.
Sign-up for Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing investment picks
2014/10/28
By Wallace Witkowski and Sue Chang, MarketWatch SAN FRANCISCO (MarketWatch) -- Facebook Inc. and Gilead Sciences Inc. shares are in focus in the extended session Tuesday, after the companies reported quarterly results following the close.
Sign-up for UPDATE: Facebook, Gilead shares slip after hours following earnings investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced safety and efficacy follow-up data on Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in patients with a baseline T315I mutation from its Phase 1 and Phase 2 PACE trials in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). With a median follow-up of three years for CP-CML patients and nine months overall, Iclusig continues to exhibit responses in patients with the T315I mutation, for whom there is no other approved tyrosine kinase inhibitor (TKI) therapy.
Sign-up for ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia investment picks
Gilead Sciences, Inc. (NASDAQ: GILD) today announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and safety profile for Zydelig ® (idelalisib) in relapsed patients with chronic lymphocytic leukemia (CLL) and two types of indolent non-Hodgkin lymphoma (iNHL). The findings are being presented this week at the Annual Meeting of the American Society of Hematology (ASH). Zydelig is indicated in the United States as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies, and in combination with rituximab for patients with relapsed CLL for whom rituximab alone would be considered appropriate therapy due to comorbidities.
Sign-up for Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma investment picks
Genesis Energy, L.P. (NYSE: GEL) will hold a follow-up conference call at 10:30 a.m. Central time regarding its third quarter earnings.
Sign-up for Genesis Energy, L.P. Third Quarter Results Follow-Up Conference Call investment picks
DALLAS, Texas Sept.
Sign-up for MoneyGram Enhances Technology Platforms Through Nexxo Follow-On Acquisition investment picks
2014/9/23
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS ), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced positive 58 week follow up data from its BOW015 efficacy and safety trial comparing BOW015, a biosimilar infliximab, to Remicade.
Sign-up for EPIRUS Announces Positive 58 Week Follow up Data for BOW015 for Treatment of Rheumatoid Arthritis investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Following Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Focused Research  |  Next: Following Results